Company intelligence / Profile preview

Ibn Al Baytar

Tunis, Tunisia

Ownership: Private
Development stage: Other

Overview

Ibn Al Baytar is a Tunisian pharmaceutical manufacturing and marketing company, acquired by Hikma Pharmaceuticals in 2010. It operates with a subsidiary, Medicef, selling 41 products in various dosage strengths across cardiovascular, respiratory, and anti-infective therapeutic areas. Following the acquisition, it became the 9th largest pharmaceutical company in Tunisia with approximately 3% market share, serving as a platform for Hikma's expansion into French-speaking African countries.

Modalities: Small molecule
Industry: Biotech

Partnerships

Hikma Pharmaceuticals (acquisition to strengthen footprint in MENA, leverage local manufacturing, and accelerate market penetration in Tunisia for regional expansion)

Beyond the preview

Go deeper on Ibn Al Baytar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ibn Al Baytar.

Explore the full profile